Multiple pathways and predicted protein targets

The term 'Multiple pathways and predicted protein targets' is a non-specific descriptor used in pharmacological research and bioinformatics to categorize drugs or compounds that lack a single, well-defined molecular target (Source: PubMed). This designation is frequently encountered in network pharmacology studies, particularly those investigating multi-component traditional medicines or polypharmacological agents that exert their effects through a complex web of interactions (Source: NIH). Rather than identifying a specific receptor or enzyme, this term indicates that the therapeutic effect is likely the result of modulating several signaling pathways and various predicted proteins simultaneously. In many cases, these targets are identified through in silico screening, molecular docking, or transcriptomic analysis rather than direct biochemical validation (Source: Nature). Consequently, this entry does not represent a distinct therapeutic target but rather a collective profile of potential biological interactions. For biotech analysts, this label suggests a high degree of target promiscuity or a systemic mechanism of action that may involve diverse molecular classes such as kinases, G protein-coupled receptors, and transcription factors. Because it is a broad category, it lacks specific biomarkers, standardized safety profiles, or a singular mechanism of action. Understanding this classification is crucial for evaluating the risk-benefit profile of compounds that do not follow the 'one drug, one target' paradigm (Source: PubMed).

Other names

Network pharmacology targetsPredicted protein targetsMulti-target profile

Polypharmacology and multi-target modulation